Clopidogrel/Tegoprazan
Alternative Names: Clopidogrel/Tegoprazan - Daehwa Pharmaceutical; DHP-2302; DHP-2302R1/DHP-2302R2; DHP-2302R2/DHP-2302R1Latest Information Update: 29 Apr 2024
At a glance
- Originator Daehwa Pharmaceutical
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Anti-ischaemics; Antibacterials; Antihaemorrhagics; Antiplatelets; Antithrombotics; Antiulcers; Benzimidazoles; Benzopyrans; Cardiovascular therapies; Chlorobenzenes; Esters; Fluorobenzenes; Ischaemic heart disorder therapies; Pyridines; Thienopyridines; Vascular disorder therapies
- Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Potassium-competitive acid blockers; Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gastrointestinal haemorrhage
Most Recent Events
- 27 Mar 2024 Daehwa Pharmaceutical plans phase III clinical trial
- 04 Mar 2024 Phase-I clinical trials in Gastrointestinal haemorrhage in South Africa (PO) (NCT06318845)